4.7 Article

Intractable Nausea and Vomiting From Autoantibodies Against a Brain Water Channel

Journal

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
Volume 11, Issue 3, Pages 240-245

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.cgh.2012.11.021

Keywords

Diagnosis; Chronic Nausea and Vomiting; Central Nervous System; Aquaporin-4 Antibody

Funding

  1. National Institutes of Health [NS49577-R01, R01 DK71209, PO1 DK068055, RO1 NS065829]
  2. Guthy Jackson Charitable Foundation
  3. National MS Society [RG 3185-B-3]
  4. Guthy-Jackson Charitable Foundation
  5. Alexion Pharmaceuticals, Inc
  6. Genzyme Corporation
  7. Mayo Clinic Foundation
  8. National Institute of Diabetes and Digestive and Kidney Diseases [U01DK073983, U01DK073975, U01DK074035, U01DK073985, U01DK074007, U01DK073974, U01DK074008]

Ask authors/readers for more resources

BACKGROUND & AIMS: Antibodies against the water channel protein aquaporin (AQP)-4 cause a spectrum of inflammatory, demyelinating, central nervous system disorders called neuromyelitis optica spectrum disorders (NMOSDs); these primarily affect the optic nerves and spinal cord but also the brain. Symptoms of intractable nausea, vomiting, and hiccups reflect involvement of AQP4 in the brainstem area postrema and account for gastroenterological presentations. We investigated the frequency of intractable nausea, vomiting, or hiccups in patients with NMOSD who tested positive for immunoglobulin G against AQP4 (AQP4-IgG). We also analyzed sera from patients with idiopathic nausea or vomiting for the presence of AQP4-IgG. METHODS: We reviewed the Mayo Clinic AQP4-IgG positive NMOSD database (n = 70) to identify patients who presented with vomiting, focusing on results from gastroenterological evaluations. We also tested serum samples (from the Gastroparesis Clinical Research Consortium repository) from patients who presented with idiopathic nausea or vomiting for AQP4-IgG (controls, n = 318 with gastroparesis and 117 without gastroparesis). RESULTS: Ten AQP4-IgG-positive patients diagnosed with NMOSD (14% of patients in the database) initially presented with intractable vomiting. Extensive gastroenterological evaluation was noninformative. AQP4-IgG was not detected in any of the controls. CONCLUSIONS: Although NMOSDs are rare, tests for AQP4-IgG should be considered for patients who present with unexplained, intractable vomiting. Detection of the antibody before the development of optic neuritis or transverse myelitis allows patients to receive immunosuppressive therapy before the development of neurologic disabilities.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available